Global CIN & HR-HPV Treatment Market Report 2023: A $17.16 Billion Market by 2027

Key Facts

The CIN & HR-HPV treatment market size was US$ 11,635.17 million in 2022, and it is projected to reach US$ 17,164.61 million by 2028; the market is estimated to record a CAGR of 6.7% from 2023 to 2028.
The market growth is attributed to an increase in the prevalence of human papillomavirus infections and favorable initiatives for preventing cervical cancer.
The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers-p16 and Ki-67-in a single cell, which is associated with HPV infections that progress to precancer or cancer if not treated on time.
HPV testing is performed for detecting cervical infection caused by high-risk mucosal HPV types that tend to cause the precancer and cancer of the cervix.